Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, Khrystal McBean, Lisa Ferguson, Jemma Larham, Jaimal Kothari, Naser Ansari-Pour, Sally Moore, Eileen Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding

Blood (2023) 142 (Supplement 1): 644.

https://doi.org/10.1182/blood-2023-182734

Published: 2023

Journal Articles

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Naser Ansari-Pour, Mohammad Kazeroun, Evie Fitzsimons, Selina J Chavda, Alessandro Lagana, Erin Flynt, Udo Oppermann, Karthik Ramasamy, Kwee Yong, Sarah Gooding, Anjan Thakurta

Blood (2023) 142 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2023-190584

Published: 2023

Journal Articles

High Throughput Risk-Adapted Monoclonal Gammopathy Community Monitoring Program

Gaurav Agarwal, Lauren Campbell, Oluremi Carty, Sally Moore, Sarah Gooding, Jaimal Kothari, Julia Evans, Jemma Larham, Lisa Ferguson, Pamela Roberts, Elizabeth Bateman, Ross Sadler, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 5077.

https://doi.org/10.1182/blood-2023-190444

Published: 2023

Journal Articles

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Blood (2023) 142 (Supplement 1): 6715.

https://doi.org/10.1182/blood-2023-188697

Published: 2023

Journal Articles

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Naser Ansari-Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, Maria Ortiz Estevez, Konstantinos Mavrommatis, Brian Walker, Gareth Morgan, Nikhil Munshi, Herve Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (6): 620–633.

https://doi.org/10.1182/blood.2022017010

Published: 2023

Includes: Supplemental data

Journal Articles

Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients

Blood (2022) 140 (Supplement 1): 1679–1681.

https://doi.org/10.1182/blood-2022-164881

Published: 2022

Journal Articles

Artificial Intelligence-Based Quantitative and Topological Analysis of Plasma Cell Burden: A New Tool for the Assessment of Myeloma

Oliver C. Lomas, Daniel Royston, Hosuk Ryou, Alan Aberdeen, Korsuk Sirinukunwattana, Karthik Ramasamy, Sarah Gooding, Jemma Larham

Blood (2022) 140 (Supplement 1): 12603–12604.

https://doi.org/10.1182/blood-2022-158525

Published: 2022

Journal Articles

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, Kubra Karagoz, Ann Polonskaia, Mirian Salazar, Evie Fitzsimons, Korsuk Sirinukunwattana, Selina Chavda, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, Anjan Thakurta

Blood (2022) 140 (16): 1816–1821.

https://doi.org/10.1182/blood.2022015909

Published: 2022

Includes: Supplemental data

Journal Articles

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 890.

https://doi.org/10.1182/blood-2021-148536

Published: 2021

Journal Articles

A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2676.

https://doi.org/10.1182/blood-2021-148692

Published: 2021

Journal Articles

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Oliver Van Oekelen, Michael Amatangelo, Manman Guo, Bhaskar Upadhyaya, Geoffrey Kelly, Manishkumar Patel, Seunghee Kim-Schulze, Alessandro Lagana, Sarah Gooding, Sundar Jagannath, William E. Pierceall, Udo Oppermann, Samir Parekh, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 730.

https://doi.org/10.1182/blood-2021-151542

Published: 2021

Journal Articles

Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients

Sarah Gooding, Naser Ansari-Pour, Mohammad H Kazeroun, Kubra Karagoz, Mirian Angulo Salazar, Evelyn Fitzsimons, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William E. Pierceall, Kwee Yong, Paresh Vyas, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 458.

https://doi.org/10.1182/blood-2021-150166

Published: 2021

Journal Articles

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Fadi Towfic, María Ortiz Estévez, Philip P. Chamberlain, Kao-Tai Tsai, Erin Flynt, Marissa Hirst, Dan Rozelle, Paula Dhiman, Paola Neri, Karthik Ramasamy, Nizar Bahlis, Paresh Vyas, Anjan Thakurta

Blood (2021) 137 (2): 232–237.

https://doi.org/10.1182/blood.2020007081

Published: 2021

Includes: Supplemental data

Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 1775.

https://doi.org/10.1182/blood-2019-126146

Published: 2019

Journal Articles

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Oliver Lomas, MD DPhil, MRCP, Sarah Gooding, MD PhD, Karthik Ramasamy, MD PhD, Angela Hamblin, MD PhD, Maite Cabes, PhD, Helene Marie-Pierre Dreau, PhD, Edward Wilson, FRCPath, MRCP

Blood (2019) 134 (Supplement_1): 3062.

https://doi.org/10.1182/blood-2019-125145

Published: 2019

Journal Articles

Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers

Fadi Towfic, PhD, Naser Ansari-Pour, PhD, Maria Ortiz, Sarah Gooding, MD PhD, Dan Rozelle, PhD, Victoria Zadorozhny, Konstantinos Mavrommatis, PhD, Sneh Lata, PhD, Nicholas Stong, PhD, Sitharthan Kamalakaran, PhD, Kao-Tai Tsai, Erin Flynt, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 365.

https://doi.org/10.1182/blood-2019-124939

Published: 2019

Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 1793.

https://doi.org/10.1182/blood-2019-126828

Published: 2019

Journal Articles

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Sarah Gooding, Chad C. Bjorklund, Michael Amatangelo, Yan Ren, Mathieu Marella, Suzana Couto, Christopher Park, Sneh Lata, Reshma Nibhani, Fadi Towfic, PhD, Udo Oppermann, Karthik Ramasamy, William E. Pierceall, Paresh Vyas, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 2648.

https://doi.org/10.1182/blood-2018-99-112644

Published: 2018

Journal Articles

Transcriptome Profiling of the Myeloma-Bone Niche Identifies BMP Signaling Role in Bone Destruction and Niche Maintenance, and Potential As a Therapeutic Target

Sarah Gooding, MD, Siobhan Webb, PhD, Sam Olechnowicz, PhD, Seint Lwin, PhD, Andrew Armitage, PhD, Karthik Ramasamy, Claire M. Edwards, PhD, Alexander Drakesmith, PhD

Blood (2016) 128 (22): 483.

https://doi.org/10.1182/blood.V128.22.483.483

Published: 2016

NARROW

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

High Throughput Risk-Adapted Monoclonal Gammopathy Community Monitoring Program

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients

Artificial Intelligence-Based Quantitative and Topological Analysis of Plasma Cell Burden: A New Tool for the Assessment of Myeloma

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Transcriptome Profiling of the Myeloma-Bone Niche Identifies BMP Signaling Role in Bone Destruction and Niche Maintenance, and Potential As a Therapeutic Target

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only